

NEXT GENERATION SUPPLY CHAINS FOR CELL & GENE THERAPIES AND ATMPs


OPEN  
**X-CELLerator**  
COMMUNITY

# *Device Supply Chain for Cell & Gene Therapies*





**Frankfurt, May 25th 2023**

**Claudia Angenendt**  
**Global Head of Supply**  
**Chain Management CGT**  
**Bayer AG**



# How are cell & gene therapies changing medical devices?



## How does this impact supply chain management?

### Variety per treatment

- Application devices
- Formulation devices
- Digital endpoint devices

### Support packages


- Individual Medical device specific for treatment
- Drug-Device-Combination (co-packed or co-referenced)
- Independent medical device

### Mode of delivery


- Treatment specific
- Infrequent to rare use
- Critical to high value treatment

# What could the supply chain set-up for devices look like?

A comparably simple example



# Let's look at one example...



# How to deal with increased complexity



## Partnering

// Select capable partners and leverage their expertise



## People

// Bring together all stakeholders for full transparency and sustainable decision making

// Finance

// Supply Chain

// Regulatory

// Development

// Quality

// Procurement



## Timing

// Start early

// Apply commercial set-up no later than phase III clinical trials

*Please feel free to  
raise any questions  
during the  
roundtable*





NEXT GENERATION SUPPLY CHAINS FOR CELL & GENE THERAPIES AND ATMPs

OPEN  
**X-CELLerator**  
COMMUNITY